Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 October 2021 | Story André Damons
Dr Nicholas Pearce, Head of the Department of Surgery in the Faculty of Health Sciences at the UFS, Prof Adrian Puren, Acting Executive Director of the National Institute for Communicable Diseases (NICD), Prof Glenda Gray, President and CEO of the South African Medical Research Council (SAMRC), and Dr Angelique Coetzee, Chairperson of the South African Medical Association (SAMA), were the panellists at the University of the Free State (UFS) Thought-Leader webinar, themed Why vaccinate?

Panellists at the University of the Free State (UFS) Thought-Leader webinar, themed Why vaccinate, felt it was critical for everyone in South Africa to get vaccinated in order to return to a sense of normality and to a university environment where lectures and learning not only happen in the lecture room, but in the ‘informal’ academic environment. 
Large numbers of the community need to be vaccinated to halt the progression of the pandemic and to maintain non-pharmaceutical interventions. 

Dr Nicholas Pearce, Head of the Department of Surgery in the Faculty of Health Sciences at the UFS, Prof Adrian Puren, Acting Executive Director for the National Institute for Communicable Diseases (NICD), Prof Glenda Gray, President and CEO of the South African Medical Research Council (SAMRC), and Dr Angelique Coetzee, Chairperson of the South African Medical Association (SAMA), were the panellists. This was the fifth webinar (28 September 2021) in the series, which is part of the Free State Literature Festival’s online initiative, VrySpraak-digitaal. 

Critical that everyone get vaccinated to return to a sense of normality

Dr Pearce indicated that patients seemed hesitant to present to both private and state health-care facilities during the COVID-19 pandemic. This resulted in patients presenting in the final stages of cancer (stages 3 and 4 as opposed to stages 1 and 2). “The quicker we are able to exit the COVID-19 pandemic – and we will probably never totally eradicate it as it might become endemic – we can go back to treating other medical conditions that are currently not being optimally managed,” said Dr Pearce.

He is also concerned that the impact of the pandemic on other medical diseases (such as mental issues) will only become visible over a number of years. We must be careful that we do not forget about the non-COVID diseases, according to Dr Pearce. 

Dr Pearce said it was critical that everyone be vaccinated in order to return to a sense of normality. The COVID-19 protocols of social distancing and the wearing of masks have left a mental toll on us as a society. He said depression and suicide are on the rise, and if we want to go back to a sense of normality, a large number of people need to get vaccinated.

The economic problems caused by COVID-19 are huge, as a large number of people have stopped their medical aids in the Free State. Some of the other economic problems due to COVID-19 is that a larger number of the younger population got infected during the third wave, which means that many breadwinners lost their lives. In the medium and long term, this is going to have huge economic repercussions. 

Vaccine acceptance increased among South African adults

Armed with figures from a recent study by the Centre for Social Change at the University of Johannesburg (UJ) in collaboration with the Developmental, Capable and Ethical State research division of the Human Sciences Research Council (HSRC), Dr Coetzee illustrated the importance of getting vaccinated. 

The study found that even though hesitancy dropped by 5%, vaccine acceptance increased to 72% among South African adults.

She said according to the study, South Africa faces two significant challenges. “First, if all 72% were actually vaccinated, we would still be 8% short of the government’s target of 80%. So, we know that government has secured significant vaccines to vaccinate the entire adult population and that the supply of vaccines should no longer be a concern as we had seen earlier this year. What we need to do is to convince some of the people who are currently hesitating about the value of getting vaccinated.”

Acceptance among the older age group has risen substantially by 11% when comparing the results from round three (December 2020 to 6 January 2021) with round four (June 2021 to July 2021). Said Dr Coetzee: “But what is still concerning is that the acceptance among those aged 18 to 24 years has actually declined from 63% to 55%.”
The second challenge that came to the fore, continued Dr Coetzee, is one of access. “We have said many times before, vaccines should be brought to the people, and not the other way around. Finally, we are now seeing that this is starting to happen, but I think it is too slow – especially in the rural areas – and maybe a bit too late. Let’s see what is going to happen going forward.”

According to Dr Coetzee, the message must be clear: We need to vaccinate to save the health-care workers and to save lives and maintain the non-pharmaceutical interventions. She said it does not matter how many times people are told to get vaccinated, they still want to take their chances with the virus. 

Aim higher to achieve herd immunity

According to Prof Puren, the threshold for herd immunity of about 67% vaccinated adults in South Africa now seems to be more mythical. “We should be aiming higher than that, meaning 90% or higher in terms of the proportion of the population being vaccinated in order for us to have a more endemic control,” says Prof Puren. 

“A large number of people in South Africa have been infected with COVID-19, but there is still a significant proportion of people that have not experienced this virus. Herd immunity is about the indirect effect of protecting those individuals who are susceptible. So, it’s a particular threshold of the number of people who had an immune response.” 

Prof Puren said there will have to be a breakthrough in infections. Vaccines do work, they are effective. It is possible for us to achieve endemic control, and vaccines are the critical component to do that. 

Important benefits of vaccination are to gain control of the academic year

“The questions about the benefits of mandatory vaccination at university – to prevent hospitalisation and deaths.  With vaccination, you also impact isolation and quarantine challenges. If you have good coverage of vaccinations, institutions will not have to keep closing classrooms, or hostels. It will help keep the workforce open. 

“One of the important benefits of vaccinations is to gain control of the academic year. All the universities have suffered, having to move to online learning where a lot of students don’t have the luxury and privilege of having data available to them all the time.”

“The issue of hybrid learning is important, and you will still see a lot of hybrid learning going on as we go into different surges. But students still need interaction, they still need face-to-face teaching, and they still need the interaction, the socialisation. We have to maximise the university experience,” said Prof Gray.  

In answering the question – would it be beneficial for employees and institutions to formulate and implement a vaccination policy – Prof Gray said it was a critical move to open up academic institutions.  

She agreed with Prof Puren that the 70% is almost mythical, and that a higher level of vaccination will be needed to start controlling the pandemic. 

“Why should we vaccinate? Why should we try and control the transmissions in our country? We have to do that, because we need our economy to start, we see how we have been affected by being on the red lists of certain countries. This affects our economy, our tourism, and jobs. A lot of people have lost jobs. If we want to interface with the rest of the world, we are going to have a discussion around making sure citizens are vaccinated.”


• The recording of the webinar can be found here  

 Passcode: nJv%p7Rp

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept